NODAL and breast cancer: In addition, treatment of both breast cancer cell lines with the Nodal antibody resulted in a significant reduction in phosphorylated Smad-2 levels as determined by Western blot analysis, suggesting a reduction of Nodal downstream signalling in the treated cells compared to non-treated or IgG treated cells (Figure 2C).